Clinical Trial Update: Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study assessing SAR440340 (anti-IL-33 mAb) for efficacy, safety, and tolerability in moderate-to-severe COPD; study completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SAR440340 (anti-IL-33 monoclonal antibody)

Snippet

Sponsor: Sanofi | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-11-22